S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

APLS Apellis Pharmaceuticals Inc

33.21

0.07 (0.21%)

21 Dec 2024 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Apellis Pharmaceuticals Charts.

Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Apellis Pharmaceuticals Charts.

Apellis Pharmaceuticals Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 14 December 2024 (1 week ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 12 December 2024 (1 week ago) • Edgar (US Regulatory)

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Saturday 7 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Wednesday 27 November 2024 (3 weeks ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 23 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Tuesday 12 November 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Saturday 9 November 2024 (1 month ago) • Edgar (US Regulatory)

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Tuesday 5 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

U.S. Index Futures Rise as Election Looms; Oil and Gold Prices Steady
Tuesday 5 November 2024 (2 months ago) • IH Market News

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 2 November 2024 (2 months ago) • Edgar (US Regulatory)

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Sunday 27 October 2024 (2 months ago) • GlobeNewswire Inc.

More Apellis Pharmaceuticals Inc News Articles

Woodside Petroleum

National Australia Bank

S&P ASX 300 Metals and M...

Gold vs US Dollar

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions